Baird lowered the firm’s price target on Cogent Biosciences (COGT) to $8 from $10 and keeps a Neutral rating on the shares. The firm updated its model following its Q4 results and sees three registrational readouts on track for 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating
- Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating
- Cogent Biosciences sees cash runway into late 2026
- Cogent Biosciences reports Q4 net loss $67.9M vs. $54.4M last year
- Cogent Biosciences exec buys $332K in common stock